Lysol Maker Reckitt Books Rise in Revenue, Boosted by Emerging Markets
By Aimee Look
Reckitt Benckiser booked higher revenue last year, with the Lysol disinfectant maker's sales boosted by progress in emerging markets as it continues efforts to engineer a turnaround.
The British consumer-goods giant, which also makes products like Durex condoms and Mucinex cold medicine, said Thursday that net sales rose to 14.21 billion pounds ($19 billion) in 2025 from 14.17 billion pounds the year before, helped by growth in emerging markets. The result slightly missed market expectations of 14.23 billion pounds, according to estimates compiled by the company.
On a like-for-like basis, sales grew 5% on year, Reckitt said.
Pretax profit jumped to 3.84 billion pounds from 2.10 billion pounds.
For the year ahead, Reckitt expects core like-for-like revenue to rise by 4% to 5%, which is in line with medium-term guidance.
Write to Aimee Look at aimee.look@wsj.com
(END) Dow Jones Newswires
March 05, 2026 02:54 ET (07:54 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States